Tag Archives: B-VEC

23May/23

The First Drug-Repeatable Gene Therapy—Beremagene Geperpavec (B-VEC)—Approved by FDA

May 23, 2023Gene Therapy NewsB-VEC, Repeatable Gene Therapybiolabs

The FDA approved Beremagene Geperpavec (B-VEC), also known by its trade name Vyjuvke, on May 19, 2023, for the treatment of dystrophic maculopapularity in patients aged 6 months and older with epidermolysisRead More…

Gene Therapy Research
Gene Therapy News